Bradycardia News and Research

RSS

Bradycardia, ("heart slowness"), as applied to adult medicine, is defined as a resting heart rate of under 60 beats per minute, though it is seldom symptomatic until the rate drops below 50 beat/min.

BMC reduced audible alarms as a way to combat alarm fatigue, improve patient safety

Boston Medical Center (BMC) successfully reduced audible alarms as a way to combat alarm fatigue and improve patient safety. The hospital, one of two in the country that spearheaded this issue, implemented a novel cost-effective approach during a six-week pilot program that resulted in a drastic drop in audible alarms.

16 Jan 2014

iRhythm Technologies’ ZIO Service detects more cardiac arrhythmias than Holter monitor

iRhythm Technologies, a healthcare information services company, today announced that a prospective study by Scripps Translational Science Institute (STSI) has found that use of the company's ZIO Service significantly increased detection of cardiac arrhythmias, compared to use of the traditional Holter monitor.

3 Jan 2014

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. today announced that the company is acquiring exclusive rights in the United States for Saphris (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc.

3 Dec 2013

Discovery Labs submits IND application to start AEROSURF phase 2 clinical program

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard of respiratory critical care, today announced that it has submitted an investigational new drug application to the U.S. Food and Drug Administration to initiate its AEROSURF phase 2 clinical program.

17 Oct 2013

St. Jude Medical completes Nanostim acquisition; leadless pacemaker receives CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced the completion of its acquisition of Nanostim, Inc., a privately-owned developer of miniaturized, leadless pacemakers.

15 Oct 2013

FDA approves Discovery Lab’s updated product specifications for SURFAXIN lucinactant

Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the U.S. Food and Drug Administration (FDA) has agreed to the Company's updated product specifications for SURFAXIN® (lucinactant) Intratracheal Suspension which was approved for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.

5 Oct 2013

Pacemakers implanted for slow heart rhythm restore life expectancy to normal levels

Pacemakers implanted for slow heart rhythm restore life expectancy to normal levels, reveals research presented at ESC Congress 2013 today by Dr Erik O. Udo from the Netherlands. The findings provide a new reference point for the prognosis of modern pacemaker patients.

2 Sep 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Excessive intake of cola and honey can cause fainting and arrhythmia symptoms, shows study

Drinking excessive amounts of cola and eating honey made from the pollen of Rhododendrons can cause unusual syncope (fainting) and symptoms of arrhythmia, report two case studies presented as abstracts at the EHRA EUROPACE 2013 meeting, in Athens 23 to 26 June.

25 Jun 2013

Sorin Group announces CE mark approval, launch of REPLY 200 family of pacemakers with SAM

Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today CE mark approval and the European commercial launch of the REPLY 200 family of pacemakers featuring Sleep Apnea Monitoring.

18 Jun 2013

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Shire plc, the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association 166th Annual Meeting in San Francisco, May 18-22.

20 May 2013

Martindale Pharma announces UK launch of Prenoxad Injection for opioid overdose

Martindale Pharma, a leader in the manufacture and supply of specialty pharmaceuticals, is pleased to announce the UK launch of Prenoxad Injection, the world's first licensed emergency treatment for acute opioid related overdose for use at home or other non-medical settings.

3 May 2013

Fish-related ciguatoxin danger highlighted

Researchers report that 28 cases of ciguatera fish poisoning occurred in New York City during 2010–2011, a greater number than were reported during the preceding 10-year period.

6 Feb 2013

Urgent research needed’ on emergency airway management

Research in JAMA adds to suspicions that advanced airway management techniques may do more harm than good in patients with out-of-hospital cardiac arrest.

16 Jan 2013

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.

14 Dec 2012

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring key sets of VIMPAT® (lacosamide) C-V data at the 66th Annual Meeting of the American Epilepsy Society (AES) in San Diego, Calif., November 30 - December 4.

29 Nov 2012

FDA approves Boston Scientific’s S-ICD system to treat sudden cardiac arrest

The U.S. Food and Drug Administration has granted Boston Scientific Corporation regulatory approval for its S-ICD System, the world's first and only commercially available subcutaneous implantable defibrillator (S-ICD) for the treatment of patients at risk for sudden cardiac arrest (SCA).

29 Sep 2012

Bradycardia News and Research

Further Reading